An NDIS participant with a chronic condition can enjoy a taxpayer-supported cruise with their support team. Does it make sense that, at the same time, they could be denied funded access to medicine or other health technology that could significantly improve their health and quality of life? Where is the equity and opportunity cost in that? …
Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?
April 23, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 - - Australian Biotech -
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech -
Is this disconnect so entrenched we can no longer recognise the presence of a problem?
November 19, 2025 - - Latest News -
Minister managing the 'double-whammy' of participant and plan growth
November 19, 2025 - - Latest News -
Tryp advances psilocin trial for binge eating disorder as second patient enrolled
November 18, 2025 - - Australian Biotech -
Nyrada advances toward Phase 2a trial of cardioprotective candidate
November 18, 2025 - - Australian Biotech -
We know they're planning something on these issues, because they told us
November 18, 2025 - - Latest News